DrugPatentWatch Database Preview
ALLERGAN SALES LLC Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for ALLERGAN SALES LLC, and when can generic versions of ALLERGAN SALES LLC drugs launch?
ALLERGAN SALES LLC has fifty-two approved drugs.
There are seventy-four US patents protecting ALLERGAN SALES LLC drugs.
There are one thousand and eighty-four patent family members on ALLERGAN SALES LLC drugs in sixty-eight countries and one hundred and thirty-two supplementary protection certificates in seventeen countries.
Summary for ALLERGAN SALES LLC
International Patents: | 1084 |
US Patents: | 74 |
Tradenames: | 52 |
Ingredients: | 38 |
NDAs: | 52 |
Patent Litigation for ALLERGAN SALES LLC: | See patent lawsuits for ALLERGAN SALES LLC |
Drugs and US Patents for ALLERGAN SALES LLC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan Sales Llc | INFED | iron dextran | INJECTABLE;INJECTION | 017441-001 | Approved Prior to Jan 1, 1982 | BP | RX | Yes | Yes | Start Trial | Start Trial | ||||
Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | AB | RX | Yes | No | 8,673,921 | Start Trial | Y | Y | Start Trial | |
Allergan Sales Llc | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-003 | Jul 25, 2013 | RX | Yes | No | 8,481,598 | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALLERGAN SALES LLC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan Sales Llc | KADIAN | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 020616-003 | Jul 3, 1996 | 5,202,128 | Start Trial |
Allergan Sales Llc | KADIAN | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 020616-006 | Oct 27, 2006 | 5,202,128 | Start Trial |
Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | 5,532,241 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALLERGAN SALES LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 2.5 mg, 5 mg, 10 mg, and 20 mg | ➤ Subscribe | 2011-12-19 |
➤ Subscribe | Tablets | 12.5 mg, 25 mg, 50 mg, and 100 mg | ➤ Subscribe | 2013-01-14 |
➤ Subscribe | Capsules | 14 mg/10 mg and 28 mg/10 mg | ➤ Subscribe | 2015-05-18 |
➤ Subscribe | Capsules | 7 mg/10 mg | ➤ Subscribe | 2016-09-26 |
➤ Subscribe | Capsules | 140 mg/125 mg/ 125 mg | ➤ Subscribe | 2014-08-12 |
➤ Subscribe | Transdermal System Extended-re | 3.9 mg/24 hrs | ➤ Subscribe | 2008-08-19 |
➤ Subscribe | Injection | 400 mg/vial and 600 mg/vial | ➤ Subscribe | 2014-10-29 |
➤ Subscribe | Capsules | 10 mg and 20 mg | ➤ Subscribe | 2005-03-30 |
➤ Subscribe | Suppository | 1000 mg | ➤ Subscribe | 2013-05-24 |
➤ Subscribe | Tablets | 5 mg/80 mg | ➤ Subscribe | 2017-06-09 |
➤ Subscribe | Extended-release Capsules | 20 mg, 40 mg, 80 mg and 120 mg | ➤ Subscribe | 2017-07-25 |
➤ Subscribe | Tablets | 10 mg, 20 mg, and 40 mg | ➤ Subscribe | 2015-01-21 |
➤ Subscribe | Capsules | 21 mg/10 mg | ➤ Subscribe | 2016-09-23 |
➤ Subscribe | Capsules | 145 mcg and 290 mcg | ➤ Subscribe | 2016-08-30 |
➤ Subscribe | Capsules | 4 mg and 8 mg | ➤ Subscribe | 2012-10-09 |
➤ Subscribe | Gel | 10% | ➤ Subscribe | 2014-06-19 |
➤ Subscribe | Capsules | 5 mg | ➤ Subscribe | 2005-08-17 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
International Patents for ALLERGAN SALES LLC Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2003294262 | Start Trial |
Australia | 621591 | Start Trial |
Cyprus | 1111061 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALLERGAN SALES LLC Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0398460 | C300221 | Netherlands | Start Trial | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 |
1480644 | CA 2016 00059 | Denmark | Start Trial | PRODUCT NAME: FARMACEUTISK BLANDING ELLER SAMMENSAETNING DER SOM AKTIVE BESTANDDELE DERAF, HERUNDER CEFTAZIDIMPENTAHYDRAT OG AVIBACTAMNATRIUM; REG. NO/DATE: EU/1/16/1109 20160628 |
1043327 | SPC/GB13/004 | United Kingdom | Start Trial | PRODUCT NAME: CEFTAROLINE FOSAMIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/12/785/001 20120823 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.